Healthcare provider profile · identity verified

Julia Lee Charmayne Pulliam, PA

Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · OREGON CITY, OR · NPI 1992761183

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Julia Lee Charmayne Pulliam, PA received $13.92 in general payments during 2025 across 1 reported records.

Abbott Laboratories accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$13.92

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Abbott Laboratories Unresolved — no canonical attribution shown $13.92100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$13.921

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
ID NOW INSTRUMENT
Normalized: id now instrument
Device Abbott Laboratories $13.92 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium23381
Levothyroxine SodiumLevothyroxine Sodium15353
Amlodipine BesylateAmlodipine Besylate15147
LisinoprilLisinopril14650
OmeprazoleOmeprazole12242
Trazodone HclTrazodone Hcl11632
Metoprolol SuccinateMetoprolol Succinate9229
Losartan PotassiumLosartan Potassium8331
GabapentinGabapentin7224
Duloxetine HclDuloxetine Hcl6821
Oxycodone HclOxycodone Hcl6720
Albuterol Sulfate HfaAlbuterol Sulfate6430
Metformin HclMetformin Hcl6322
SimvastatinSimvastatin5820
EliquisApixaban5217
Sertraline HclSertraline Hcl5016
HydrochlorothiazideHydrochlorothiazide4520
Pantoprazole SodiumPantoprazole Sodium4513
Bupropion XlBupropion Hcl4411
Tamsulosin HclTamsulosin Hcl4316
Tizanidine HclTizanidine Hcl4212
FamotidineFamotidine37suppressed
FurosemideFurosemide3517
AlprazolamAlprazolam3411
CarvedilolCarvedilol34suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst3427
Rosuvastatin CalciumRosuvastatin Calcium3412
Citalopram HbrCitalopram Hydrobromide32suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide3213
MounjaroTirzepatide31suppressed
LovastatinLovastatin30suppressed
LamotrigineLamotrigine29suppressed
AtenololAtenolol28suppressed
AzithromycinAzithromycin2826
ClopidogrelClopidogrel Bisulfate27suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2716
Potassium ChloridePotassium Chloride2715
Quetiapine FumarateQuetiapine Fumarate27suppressed
Fluticasone PropionateFluticasone Propionate26suppressed
RisperidoneRisperidone25suppressed
Oxybutynin Chloride ErOxybutynin Chloride24suppressed
OzempicSemaglutide24suppressed
Donepezil HclDonepezil Hcl23suppressed
Escitalopram OxalateEscitalopram Oxalate23suppressed
Pravastatin SodiumPravastatin Sodium23suppressed
Fluoxetine HclFluoxetine Hcl22suppressed
Alendronate SodiumAlendronate Sodium21suppressed
EstradiolEstradiol21suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21suppressed
Metoprolol TartrateMetoprolol Tartrate21suppressed
SpironolactoneSpironolactone21suppressed
Buspirone HclBuspirone Hcl20suppressed
FinasterideFinasteride20suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl1915
Ondansetron OdtOndansetron1715
PrednisonePrednisone1711
Venlafaxine Hcl ErVenlafaxine Hcl17suppressed
Bupropion Hcl SrBupropion Hcl16suppressed
Montelukast SodiumMontelukast Sodium16suppressed
Paroxetine HclParoxetine Hcl16suppressed
Testosterone CypionateTestosterone Cypionate16suppressed
CephalexinCephalexin1511
Ciprofloxacin HclCiprofloxacin Hcl1514
IbuprofenIbuprofen15suppressed
PaxlovidNirmatrelvir/Ritonavir1515
TopiramateTopiramate15suppressed
TrulicityDulaglutide15suppressed
Benazepril HclBenazepril Hcl14suppressed
FluconazoleFluconazole1412
Propranolol HclPropranolol Hcl14suppressed
Ropinirole HclRopinirole Hcl14suppressed
Spiriva HandihalerTiotropium Bromide14suppressed
ValacyclovirValacyclovir Hcl14suppressed
XareltoRivaroxaban14suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1313
Metformin Hcl ErMetformin Hcl13suppressed
MirtazapineMirtazapine13suppressed
Tramadol HclTramadol Hcl13suppressed
Warfarin SodiumWarfarin Sodium13suppressed
Zolpidem TartrateZolpidem Tartrate13suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12suppressed
Glipizide ErGlipizide12suppressed
LorazepamLorazepam12suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12suppressed
Hydroxyzine PamoateHydroxyzine Pamoate11suppressed
MeloxicamMeloxicam11suppressed
Memantine HclMemantine Hcl11suppressed
Pramipexole DihydrochloridePramipexole Di-Hcl11suppressed
TorsemideTorsemide11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $13.92 · 1 records Abbott Laboratories ID NOW INSTRUMENT
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error